|
N
|
39
|
149
| |
38
|
150
| |
|
Age (year), median [IQR]
|
40 [33–44]
|
43 [36–52]
|
0.0349*
|
45 [37–53]
|
42 [35–51]
|
0.2683
|
|
Age < 50 (n, %)
|
35 (90%)
|
101 (68%)
|
0.0051*
|
25 (66%)
|
111 (74%)
|
0.3166
|
|
Males (n, %)
|
39 (100%)
|
146 (98%)
|
1.000
|
38 (100%)
|
147 (98%)
|
1.000
|
|
Assumed route of HIV-1 infection (n, %)
| | |
0.7044
| | |
0.1995
|
|
Homosexual
|
34 (87%)
|
123 (83%)
| |
35 (92%)
|
122 (81%)
| |
|
Heterosexual
|
4 (10%)
|
23 (15%)
| |
2 (5%)
|
25 (17%)
| |
|
Others
|
1 (3%)
|
3 (2%)
| |
1 (3%)
|
3 (2%)
| |
|
Japanese (n, %)
|
38 (97%)
|
148 (99%)
|
0.3727
|
38 (100%)
|
148 (99%)
|
1.0000
|
|
CD4+ cell count (cell/μL), median [IQR]
|
491 [396–659]
|
535 [443–736]
|
0.271
|
531 [419–711]
|
538[442–735]
|
0.5293
|
|
HIV-1-RNA level (copies/mL), median [IQR]
|
< 20 [< 20–< 20]
|
< 20 [< 20–< 20]
|
0.5856
|
< 20 [< 20–< 20]
|
< 20 [< 20–< 20]
|
0.9208
|
|
Abacavir use (n, %)
|
7 (18%)
|
52 (35%)
|
0.0523
|
9 (24%)
|
50 (33%)
|
0.3285
|
|
Tenofovir use (n, %)
|
30 (77%)
|
92 (62%)
|
0.0911
|
28 (74%)
|
94 (63%)
|
0.2548
|
|
Protease inhibitor use (n, %)
|
10 (26%)
|
65 (44%)
|
0.0449*
|
14 (37%)
|
61 (41%)
|
0.7140
|
|
Darunavir use (n, %)
|
10 (26%)
|
51 (34%)
|
0.3428
|
9 (24%)
|
52 (35%)
|
0.2458
|
|
Atazanavir use (n, %)
|
0 (0%)
|
4 (3%)
|
0.5820
|
1 (3%)
|
3 (2%)
|
1.0000
|
|
Lopinavir use (n, %)
|
0 (0%)
|
5 (4%)
|
0.5854
|
3 (8%)
|
2 (1%)
|
0.0571
|
|
Fosamprenavir use (n, %)
|
0 (0%)
|
5 (3%)
|
0.5854
|
1 (3%)
|
4 (3%)
|
1.0000
|
|
Integrase inhibitor use (n, %)
|
24 (62%)
|
73 (49%)
|
0.2079
|
24 (63%)
|
73 (49%)
|
0.1457
|
|
Duration of ART (year), median [IQR]
|
3.8 [1.8–6.3]
|
4.4 [2.4–6.6]
|
0.2283
|
3.4 [1.8–5.9]
|
4.4 [2.5–6.7]
|
0.0438*
|
|
Frequency of ART exchange, median [IQR]
|
0 [0–1]
|
1 [0–2]
|
0.4936
|
0 [0–1]
|
1 [0–2]
|
0.0607
|
|
Comorbidities
|
|
Chronic renal disease (n, %)
|
3 (8%)
|
18 (12%)
|
0.5747
|
2 (5%)
|
19 (13%)
|
0.2572
|
|
Chronic hepatitis B (n, %)
|
3 (8%)
|
13 (9%)
|
1.0000
|
2 (5%)
|
14 (9%)
|
0.5333
|
|
Dyslipidemia (n, %)
|
6 (15%)
|
49 (33%)
|
0.0476*
|
12 (31%)
|
43 (29%)
|
0.6957
|
|
Statin use (n, %)
|
1 (3%)
|
13 (9%)
|
0.3072
|
1 (3%)
|
13 (9%)
|
0.3078
|
|
Hypertension (n, %)
|
3 (8%)
|
18 (12%)
|
0.5747
|
6 (16%)
|
15 (10%)
|
0.3850
|
|
Diabetes mellitus (n, %)
|
1 (3%)
|
12 (8%)
|
0.3088
|
6 (16%)
|
7 (5%)
|
0.0266*
|
|
Laboratory test
|
|
Serum C-reactive protein (mg/dL)
|
0.05 [0.02–0.10]
|
0.06 [0.03–0.17]
|
0.2224
|
0.10 [0.04–0.46]
|
0.05 [0.03–0.11]
|
0.0073*
|
